These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23798363)

  • 1. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.
    Mahévas M; Ebbo M; Audia S; Bonnotte B; Schleinitz N; Durand JM; Chiche L; Khellaf M; Bierling P; Roudot-Thoraval F; Godeau B; Michel M
    Am J Hematol; 2013 Oct; 88(10):858-61. PubMed ID: 23798363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
    Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
    Zaja F; Vianelli N; Volpetti S; Battista ML; Defina M; Palmieri S; Bocchia M; Medeot M; De Luca S; Ferrara F; Isola M; Baccarani M; Fanin R
    Eur J Haematol; 2010 Oct; 85(4):329-34. PubMed ID: 20546023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.
    Gómez-Almaguer D; Tarín-Arzaga L; Moreno-Jaime B; Jaime-Pérez JC; Ceballos-López AA; Ruiz-Argüelles GJ; Ruiz-Delgado GJ; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Sánchez-Cárdenas M
    Eur J Haematol; 2013 Jun; 90(6):494-500. PubMed ID: 23470153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
    Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
    Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients.
    D'Arena G; Capalbo S; Laurenti L; Del Poeta G; Nunziata G; Deaglio S; Spinosa G; Tarnani M; De Padua L; Califano C; Ferrara F; Cascavilla N
    Eur J Haematol; 2010 Dec; 85(6):502-7. PubMed ID: 20846302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC; Wang W; Zhou YH; Wang XM; Wang X; Wang YL; Sun GZ; Hou M
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
    Routy B; Boulassel MR; Spurll GM; Warner MN; Routy JP
    Am J Ther; 2013; 20(2):219-22. PubMed ID: 23466621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
    Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.
    Brah S; Chiche L; Fanciullino R; Bornet C; Mancini J; Schleinitz N; Jean R; Kaplanski G; Harlé JR; Durand JM
    Ann Hematol; 2012 Feb; 91(2):279-85. PubMed ID: 21710166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R
    Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F; Battista ML; Pirrotta MT; Palmieri S; Montagna M; Vianelli N; Marin L; Cavallin M; Bocchia M; Defina M; Ippoliti M; Ferrara F; Patriarca F; Avanzini MA; Regazzi M; Baccarani M; Isola M; Soldano F; Fanin R
    Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.
    Moulis G; Lapeyre-Mestre M; Mahévas M; Montastruc JL; Sailler L
    Am J Hematol; 2015 Apr; 90(4):301-5. PubMed ID: 25557586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.